JAMA Psychiatry

Systematic Review: Greater exposure to adverse was associated with abnormalities in spectrum conditions, linking SDOHs to clinical outcomes and supporting equity-oriented approaches.

https://ja.ma/4agfHNI

The FDA approved gepirone extended release for based on 2 positive trials despite 11 negative or inconclusive trials, highlighting the agency's use of regulatory flexibility and trial-level statistical significance.

Assessing Drug Efficacy After Multiple Negative Trials This Special Communication reviews the US Food and Drug Administration evaluation of 1 investigational drug (gepirone extended release) for major depressive disorder with conflicting evidence of benefit.

Individualized, connectivity-based targeting of accelerated transcranial magnetic stimulation produced significantly greater antidepressant effects than scalp-based targeting in adults with treatment-resistant .

https://ja.ma/43VEDX1